

## Determination of $K_D$ -values of various fluorobenzylated Glibenclamide derivatives

R. Schirmmacher<sup>a</sup>, A. Korobeinikov<sup>a</sup>, A. Schneider<sup>b</sup>, M. Schwanstecher<sup>c</sup>, F. Rösch<sup>a</sup>

<sup>a</sup>Institut für Kernchemie, Johannes Gutenberg-Universität Mainz; <sup>b</sup>1. Med. Klinik, Johannes Gutenberg-Universität Mainz; <sup>c</sup>Institut für Pharmakologie und Toxikologie, Universität Braunschweig


**Aim.** The present study was conducted to obtain reliable binding affinity data about some novel fluorobenzylated glibenclamide derivatives. These data are important for finding the most suitable compound among a great variety of new fluoroalkylated and fluorobenzylated glibenclamide derivatives for the use as PET ligands for the quantification and visualisation of the sulfonylurea receptor (SUR1). The new fluorobenzylated derivatives show a high binding affinity for SUR1 which is a prerequisite for further investigation.

**Materials.** [<sup>3</sup>H]glibenclamide (specific activity 51 Ci mmol<sup>-1</sup>) was purchased from NEN (Dreieich, Germany). Stock solutions of all drugs were prepared in KOH (50 mM) or dimethyl sulfoxide with a final solvent concentration in the media below 1 %.


**Binding assays.** Transfections and membrane preparations were performed as described (Schwanstecher et al., 1992, 1998). Briefly, COS-1 cells cultured in DMEM HG (10 mM glucose), supplemented with 10 % fetal calf serum (FCS), were plated at a density of  $5 \times 10^5$  cells per dish (94 mm) and allowed to attach overnight. 200 µg of pECE-human SUR1 complementary DNA (GenBank NP\_000343) were used to transfect 10 plates. For transfection the cells were incubated 4 hours in a Tris-buffered salt solution containing DNA (5 - 10 µg/ml) plus DEAE-dextran (1 mg/ml), 2 min in HEPES-buffered salt solution plus dimethyl sulfoxide (10 %) and 4 hours in DMEM-HG plus chloroquine (100 µM). Cells were then returned to DMEM-HG plus 10 % FCS and were used 60-72 hours post transfection to prepare membranes as described (Schwanstecher et al., 1992). To measure binding to membranes from COS-cells the resuspended fraction (final protein concentration 5 - 50 µg/ml) was incubated in "Tris-buffer" (50 mM, pH 7.4) containing [<sup>3</sup>H]glibenclamide (final concentration 0.3 nM, nonspecific binding defined by 1 µM glibenclamide) and other additions as shown in the figure. Incubations were carried out for 1 h at room temperature and were terminated by rapid filtration through Whatman GF/B filters.

**Data.** Half-maximally inhibitory drug-concentrations (IC<sub>50</sub> values) and Hill coefficients (n) were estimated by fitting the function  $B = 1/(1+([\text{drug}]/IC_{50})^n)$  to the data of each single displacement experiment.  $K_D$ s were calculated from IC<sub>50</sub> values as described (Schwanstecher et al., 1992). Data shown as means ± S.E.M.

**Results:** Competition binding experiments were performed to assess the affinity of the glibenclamide analogues for binding to human SUR1 (figure). Unlabelled glibenclamide and substances 1-5 induced complete monophasic inhibition curves with Hill coefficients close to 1 (0.91 - 1.04) yielding dissociation constants ( $K_D$ s) of 0.28 nM, 0.25 nM, 0.55 nM, 1.37 nM, 0.24 nM and 0.28 nM, respectively (figure; table).



X	entry	$K_D$ (nmol)	nH
	Glyburide	$0.28 \pm 0.02$	$0.96 \pm 0.03$
Cl	S1	$0.25 \pm 0.03$	$1.04 \pm 0.03$
F	S2	$0.55 \pm 0.11$	$0.92 \pm 0.04$
H	S3	$1.37 \pm 0.25$	$0.91 \pm 0.04$
Br	S4	$0.24 \pm 0.01$	$1.02 \pm 0.04$
I	S5	$0.28 \pm 0.02$	$0.96 \pm 0.03$



The determination of  $K_D$  values of different substituted glibenclamide derivatives with less lipophilic properties is currently under investigation. The final aim of this study is to label the most suitable ligand with fluorine-18 in order to determine the beta-cell mass of the endocrine pancreatic tissue *in vivo* with positron emission tomography (PET).

**References:** Schwanstecher M, Brandt Ch, Behrends S, Schaupp U and Panten U (1992) *Br J Pharmacol* 106: 295-301. / Schwanstecher M, Sieverding C, Dörschner H, Gross I, Aguilar-Bryan L, Schwanstecher C, Bryan J (1998) *EMBO J* 17:5529-5535.